Our products

Cryogenic infrastructure
at API facility

Polpharma is able to meet these challenges thanks to the […]

Liophilization: What does a strawberry
have in common with Polpharma API? 

On November 2022, at Polpharma API Plant, we implemented freeze-drying […]

Polpharma’s strategic investment in HPAPI facility, the first of this kind in Poland

In 2022, we are opening a new chapter in the […]

Safe approach in delivering nitrosamine-free API products

N-nitrosamine impurities have been in the news for some years […]

Polpharma partners with Pikralida biopharmaceutical start-up

Polpharma has established cooperation with Pikralida, a biopharmaceutical start-up that […]

September 2019 was the date when the transformation process started in the API Business Unit of Polpharma.

This process targets clear information flow from an efficiency perspective based on KPIs, facilitating rapid…

Searching for new, better, and innovative solutions. Digital Transformation at Polpharma API.

People and their ability to change are the key drivers of each transformation.

Polpharma API Business Unit (API BU) completed step 1. Risk Evaluation according to EMA’s request concerning presence of nitrosamines in drug products.

As of September 26, 2019, EMA’s Human Medicines Committee (CHMP) requested as a matter of…

Why particles size is important in pharmaceutical industry? Is it really problematic?

In the pharmaceutical industry, particle size has become one of the key aspects in the…